Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Oct;24(10):805-10.
doi: 10.2165/11584260-000000000-00000.

Abuse-deterrent and Tamper-Resistant Opioid Formulations: What Is Their Role in Addressing Prescription Opioid Abuse?

Affiliations
Review

Abuse-deterrent and Tamper-Resistant Opioid Formulations: What Is Their Role in Addressing Prescription Opioid Abuse?

Jennifer P Schneider et al. CNS Drugs. .

Abstract

About one in every three individuals will experience chronic pain in their lifetime, and opioids are known to be an effective means to treat this condition. Much attention, however, has been given to the fact that prescription opioid analgesics are some of the most frequently abused drugs, and misuse is prominent in patients with chronic pain. Several new opioid formulations that are designed to prevent or deter the abuse of opioids are currently in development, and two have been approved for marketing (morphine sulphate co-formulated with naltrexone hydrochloride [Embeda®] and a new formulation of the extended-release oxycodone [OxyContin®]). In this article, we review the various types of abuse-deterrent and tamper-resistant formulations in clinical development. We believe that continued advances in opioid formulations can help mitigate risk for those with legitimate need for pain control, but only if used rationally in the context of good clinical practice.

Similar articles

See all similar articles

Cited by 20 articles

See all "Cited by" articles

References

    1. J Child Adolesc Psychopharmacol. 2009 Oct;19(5):575-82 - PubMed
    1. Arch Otolaryngol Head Neck Surg. 2007 Oct;133(10):974-9 - PubMed
    1. Sleep. 2005 Aug 1;28(8):1007-13 - PubMed
    1. Pediatrics. 2005 Jan;115(1 Suppl):257-65 - PubMed
    1. Sleep. 2000 Dec 15;23(8):1043-51 - PubMed

Publication types

LinkOut - more resources

Feedback